Published on
August 8, 2023
- 20:01 GMT
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for Potential Commercial Launch of Lifileucel as First Approved …
Distribution channels:
Business & Economy, Technology
...
